Theralase chooses most deadly over most common cancer ......for it's next trial
There are around 300,000 GBM cases globally every year. Around 38% of those patients will be dead within a year of diagnosis. Less than 7% will survive more than 5 years.
There are over 2,000,000 NSCLC cases annually. If it is caught early 70% - 92% of these patients could still be alive at 5 years.
So ir seems Theralase has chosen the most difficult to treat, less potentially profitable cancer indication for it's next trial.
A big win with GBM will demonstrate very quickly and very clearly what X-ray activated Rutherrin can accomplish and could definitively change attitudes towards oncological pdt.